 |
138 Diseases |  |
93 Trials |
|
93 Trials |  |
2194 News |  |
| «12...2021222324252627282930...3334» |
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Clinical, Adverse events: But we also teach patients that the new oral drug is a disaster when it comes to cost, effectiveness, and side effects, principal investigators who contacted me agreed with all of that noting it has all of the same problems lupron does (Twitter) - May 1, 2019
- | Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis (clinicaltrials.gov) - Apr 29, 2019
P3, N=320, Not yet recruiting, Sponsor: ASKA Pharmaceutical Co., Ltd.
- | Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Eligard (leuprolide acetate) / TOLMAR, Astellas, Sanofi
Clinical, Journal: Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression. (Pubmed Central) - Apr 26, 2019
Women with suspected endometriosis and aberrant endometrial BCL6 expression have worse reproductive outcomes following embryo transfer, including a high miscarriage rate, poor IR, and low LBR and CPR compared to cycles pre-treated with medical and surgical management.
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: CRONOS II: Evaluation of Diet and Exercise in Prostate Cancer Patients (clinicaltrials.gov) - Apr 24, 2019
P=N/A, N=1300, Recruiting, Sponsor: AbbVie
Women with suspected endometriosis and aberrant endometrial BCL6 expression have worse reproductive outcomes following embryo transfer, including a high miscarriage rate, poor IR, and low LBR and CPR compared to cycles pre-treated with medical and surgical management. Trial completion date: Aug 2022 ->Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Combination therapy: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer (clinicaltrials.gov) - Apr 20, 2019
P1, N=25, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial completion date: Aug 2022 ->Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021 Trial completion date: Jan 2019 --> Jan 2020
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date: Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) (clinicaltrials.gov) - Apr 19, 2019
P2, N=38, Active, not recruiting, Sponsor: Duke University
Trial completion date: Jan 2019 --> Jan 2020 Trial completion date: Mar 2019 --> Jun 2019
- | Livial (tibolone) / Organon, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) - Apr 19, 2019
P4, N=50, Not yet recruiting, Sponsor: University of Cagliari
Trial completion date: Mar 2019 --> Jun 2019 Trial completion date: Mar 2017 --> May 2020 | Trial primary completion date: Dec 2016 --> Dec 2019
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, HEOR: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Apr 18, 2019
P2, N=257, Recruiting, Sponsor: Palleos Healthcare GmbH
Trial completion date: Mar 2017 --> May 2020 | Trial primary completion date: Dec 2016 --> Dec 2019 Trial completion date: Nov 2024 --> Feb 2024
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial initiation date, Trial withdrawal: GRAET: GnRH Agonist at Embryo Transfer: IVF Outcomes (clinicaltrials.gov) - Apr 16, 2019
P3, N=0, Withdrawn, Sponsor: Maimonides Medical Center
Trial completion date: Nov 2024 --> Feb 2024 Initiation date: Nov 2018 --> Apr 2019 | Not yet recruiting --> Withdrawn | N=442 --> 0
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
I had Casodex for 3 weeks and then Lupron for a year. All of it was covered by the government. (Twitter) - Apr 15, 2019
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Combination therapy, Metastases: Young-PEARL: A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC (clinicaltrials.gov) - Apr 8, 2019
P2, N=182, Active, not recruiting, Sponsor: Samsung Medical Center
Initiation date: Nov 2018 --> Apr 2019 | Not yet recruiting --> Withdrawn | N=442 --> 0 Recruiting --> Active, not recruiting
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Also do not know if you would want to follow labs on these guys. T replacement is not universal dosing, there are 7-10 different ways to replace and clomid an option. Just saying it’s not like starting lupron. It’s an art that takes time in the office, staff, lab etc. (Twitter) - Apr 6, 2019
- | New P2 trial, Surgery: PLATO: PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate (clinicaltrials.gov) - Apr 3, 2019
P2, N=122, Not yet recruiting, Sponsor: Seoul National University Hospital
- ||||| Erleada (apalutamide) / J&J
New P2 trial, Combination therapy: SAVE: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (clinicaltrials.gov) - Apr 2, 2019
P2, N=202, Not yet recruiting, Sponsor: Cancer Research Antwerp
- |||| Firmagon (degarelix) / Astellas, Ferring
Trial completion date, Trial primary completion date, Adverse events, Metastases: PRONOUNCE: A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (clinicaltrials.gov) - Mar 28, 2019
P3, N=900, Recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Mar 27, 2019
P3, N=3253, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jul 2021 Initiation date: Feb 2014 --> Nov 2016
- || Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Proposed mechanism by which KGF and lupron would work if true? (Twitter) - Mar 26, 2019
- ||| Lupron Depot (leuprorelin depot) / AbbVie, Takeda
Now at #EBMT19 @sloan_kettering Christina Cho reporting results of our Ph 2 trial using KGF/Lupron to enhance immune recovery post CD34 selected alloHCT, preclinical work by @vandenBrinkLab @Dudakov_Lab @EnricoVelardi @DrMvandenBrink #bmtsm (Twitter) - Mar 26, 2019
- | orteronel (TAK 700) / Takeda
Trial completion date, Trial primary completion date: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Mar 14, 2019
P3, N=239, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Initiation date: Feb 2014 --> Nov 2016 Trial completion date: Jun 2024 --> Jun 2029 | Trial primary completion date: Jun 2020 --> Jun 2025
- | Erleada (apalutamide) / J&J
Trial completion date, Trial initiation date: SOLAR: Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer (clinicaltrials.gov) - Mar 8, 2019
P2, N=28, Recruiting, Sponsor: VA Office of Research and Development
Trial completion date: Jun 2024 --> Jun 2029 | Trial primary completion date: Jun 2020 --> Jun 2025 Trial completion date: Sep 2022 --> Jun 2023 | Initiation date: Dec 2017 --> Jul 2018
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Mar 5, 2019
P3, N=3254, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2022 --> Jun 2023 | Initiation date: Dec 2017 --> Jul 2018 Trial completion date: Nov 2019 --> May 2021
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 26, 2019
P1, N=26, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial completion date: Nov 2019 --> May 2021 Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer (clinicaltrials.gov) - Feb 20, 2019
P2, N=57, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Dec 2018 --> Apr 2020
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Feb 5, 2019
P3, N=3256, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Dec 2018 --> Apr 2020 Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Feb 2014
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Feb 1, 2019
P3, N=3775, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Feb 2014 Active, not recruiting --> Recruiting
- || Piqray (alpelisib) / Novartis
Trial completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jan 30, 2019
P2, N=336, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial completion date: Apr 2020 --> Nov 2020
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 29, 2019
P2, N=72, Active, not recruiting, Sponsor: University of Michigan Rogel Cancer Center
Trial completion date: Apr 2020 --> Nov 2020 Trial primary completion date: Jul 2018 --> Sep 2017
- ||| Piqray (alpelisib) / Novartis
Enrollment change, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jan 23, 2019
P2, N=336, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2018 --> Sep 2017 N=160 --> 336
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Jan 8, 2019
P3, N=3775, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=160 --> 336 Initiation date: Sep 2012 --> Nov 2016
- | docetaxel / Generic mfg.
Trial completion date, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Dec 28, 2018
P1, N=20, Active, not recruiting, Sponsor: Medical University of South Carolina
Initiation date: Sep 2012 --> Nov 2016 Trial completion date: Dec 2018 --> Dec 2019
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: The Relation of GnRH Treatment to QTc Interval in Transgender Females (clinicaltrials.gov) - Dec 26, 2018
P=N/A, N=3, Terminated, Sponsor: University of California, San Francisco
Trial completion date: Dec 2018 --> Dec 2019 N=23 --> 3 | Trial completion date: Jan 2020 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Aug 2017; investigator has left UCSF
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: CCRO025: Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (clinicaltrials.gov) - Dec 21, 2018
P=N/A, N=29, Recruiting, Sponsor: University of California, Davis
N=23 --> 3 | Trial completion date: Jan 2020 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Aug 2017; investigator has left UCSF Trial completion date: Oct 2018 --> Sep 2019 | Trial primary completion date: Oct 2018 --> Sep 2019
- |||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants (clinicaltrials.gov) - Dec 21, 2018
P4, N=307, Completed, Sponsor: Takeda
Trial completion date: Oct 2018 --> Sep 2019 | Trial primary completion date: Oct 2018 --> Sep 2019 Active, not recruiting --> Completed
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: CRONOS II: Evaluation of Diet and Exercise in Prostate Cancer Patients (clinicaltrials.gov) - Dec 20, 2018
P=N/A, N=1300, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Trial completion date: Jul 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Aug 2022
- | Visanne (dienogest) / Mochida, Bayer
New trial: Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis (clinicaltrials.gov) - Dec 19, 2018
P, N=5000, Completed, Sponsor: Taipei Veterans General Hospital, Taiwan
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Enrollment change: A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants (clinicaltrials.gov) - Dec 5, 2018
P=N/A, N=108, Completed, Sponsor: Takeda
Trial completion date: Jul 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Aug 2022 Recruiting --> Completed | N=300 --> 108
- | leuprolide acetate for depot suspension / Generic mfg.
Phase classification, Enrollment change, Gene Expression Profile, Biopsy: Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation (clinicaltrials.gov) - Nov 21, 2018
P4, N=7, Terminated, Sponsor: UConn Health
Recruiting --> Completed | N=300 --> 108 Phase classification: P=N/A --> P4 | N=20 --> 7
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Nov 15, 2018
P2, N=56, Recruiting, Sponsor: University of Colorado, Denver
Phase classification: P=N/A --> P4 | N=20 --> 7 Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Mar 2019
- | Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date, Metastases: HERO: A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Nov 15, 2018
P3, N=1100, Recruiting, Sponsor: Myovant Sciences GmbH
Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Mar 2019 Trial completion date: Apr 2020 --> Jul 2020
- | Kisqali (ribociclib) / Novartis
Enrollment closed, Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Nov 8, 2018
P3, N=3258, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2020 --> Jul 2020 Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., flutamide / Generic mfg.
Trial completion date: Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer (clinicaltrials.gov) - Nov 5, 2018
P3, N=226, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012 Trial completion date: Sep 2018 --> Sep 2019
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date: Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) (clinicaltrials.gov) - Nov 2, 2018
P2, N=38, Active, not recruiting, Sponsor: Duke University
Trial completion date: Sep 2018 --> Sep 2019 Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2018
- | Yselty (linzagolix) / Kissei, Syneos Health
Enrollment closed: Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis (clinicaltrials.gov) - Oct 31, 2018
P2, N=0, Active, not recruiting, Sponsor: Kissei Pharmaceutical Co., Ltd.
Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2018 Recruiting --> Active, not recruiting
- || leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) (clinicaltrials.gov) - Oct 29, 2018
P3, N=40, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | valacyclovir / Generic mfg.
Enrollment open, Combination therapy, Surgery, Gene therapy: Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery (clinicaltrials.gov) - Oct 25, 2018
P2, N=60, Recruiting, Sponsor: The Methodist Hospital System
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) (clinicaltrials.gov) - Oct 3, 2018
P3, N=40, Not yet recruiting, Sponsor: AbbVie
- | progesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea (clinicaltrials.gov) - Oct 2, 2018
P=N/A, N=80, Active, not recruiting, Sponsor: University of Chicago
Not yet recruiting --> Recruiting Trial completion date: Aug 2017 --> Jan 2019 | Trial primary completion date: Aug 2017 --> Jan 2019
- | Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Sep 28, 2018
P2, N=7, Active, not recruiting, Sponsor: Midwestern Regional Medical Center
Trial completion date: Aug 2017 --> Jan 2019 | Trial primary completion date: Aug 2017 --> Jan 2019 Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
- | leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: Comparative Study Between ICSI Results in Transvaginal Ultrasound Guided Embryo Transfer and Transabdominal Ultrasound Guided Embryo Transfer (clinicaltrials.gov) - Sep 25, 2018
P4, N=120, Not yet recruiting, Sponsor: Cairo University
- | Trial completion, Enrollment change, Trial completion date: Regulation of Cervical Mucus Secretion (clinicaltrials.gov) - Sep 21, 2018
P4, N=7, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Active, not recruiting --> Completed | N=10 --> 7 | Trial completion date: Jul 2018 --> Aug 2017